Last Updated : May 18, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Eylea | Aflibercept | Macular edema, diabetic | List with clinical criteria and/or conditions | Complete | ||
| Harvoni | Ledipasvir / Sofosbuvir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
| Cimzia | Certolizumab pegol | Arthritis, psoriatic | List with criteria/condition | Complete | ||
| Esbriet | Pirfenidone | Idiopathic pulmonary fibrosis | List with criteria/condition | Complete | ||
| Yervoy | Ipilimumab | First Line Advanced Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Aptiom | Eslicarbazepine acetate | Epilepsy, partial-onset seizures | List with criteria/condition | Complete | ||
| Elelyso | Taliglucerase alfa | Gaucher disease | Do not list | Complete | ||
| Imbruvica | Ibrutinib | Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Gazyva | Obinutuzumab | Chronic Lymphocytic Leukemia | Reimburse | Complete | ||
| Zaxine | Rifaximin | Hepatic encephalopathy | List with criteria/condition | Complete |
Last Updated : May 18, 2024